Why Cytokinetics, Incorporated (CYTK) stock moved
No significant move on Nov 20, 2026 (−1.3%, close-to-close). Latest notable session: Nov 17, 2026.
Why Cytokinetics, Incorporated (CYTK) fell 2.9% on November 17, 2026
Cytokinetics, Incorporated (CYTK) fell 2.9% on November 17, 2026, closing at $51.65 versus $53.17 the prior session (close-to-close, from daily closes). Despite touting MYQORZO launch momentum and announcing plans for a new FDA filing, per MarketBeat. Volume was 306,024 shares (90 min in), tracking 0.67x the historical average for this time—below-average participation suggests retail and institutional investors are stepping back despite the positive product news. Source: marketbeat.com.
Cytokinetics declined 2.33% to $51.93 despite touting MYQORZO launch momentum and announcing plans for a new FDA filing, per MarketBeat. Volume was 306,024 shares (90 min in), tracking 0.67x the historical average for this time—below-average participation suggests retail and institutional investors are stepping back despite the positive product news.
What to watch next: Cytokinetics earnings on 2027-02-23 (tentative); monitor for MYQORZO revenue ramp and timing of the announced FDA filing submission.
Earlier sessions that moved CYTK
- −5.3%Cytokinetics announced expanded prescribing information for MYQORZO® (aficamten) incorporating Phase 3 MAPLE-HCM trial data, positioning the drug for a new heart-disease indication (Globe Newswire, 2026-11-16).
- −4.0%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +4.2%After presenting new efficacy data for aficamten in obstructive and non-obstructive hypertrophic cardiomyopathy at the HCMS/AHA 2026 conference.
- +2.7%Cytokinetics presented new aficamten efficacy data for obstructive and non-obstructive hypertrophic cardiomyopathy at HCMS/AHA 2026.
- −3.3%Following post-earnings profit-taking after the company beat Q3 revenue and loss estimates on November 4 with $47.6M in total revenue and strong MYQORZO® sequential growth, per the web catalyst.
- −12.7%Cytokinetics filed a material event (8-K) and an earnings report today, triggering an 11.72% intraday decline to $56.15 from $63.60. Read the November 5, 2026 analysis →
- −3.1%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +2.9%After the company presented additional ACACIA-HCM trial data on aficamten's exercise performance, dosing, and safety in non-obstructive HCM.
- −4.4%Following a Wall Street Zen analyst downgrade from hold to sell, citing widening net losses driven by heavy commercialization and R&D spending against early MYQORZO commercial revenues (web_catalyst).
- −2.6%📉 Cytokinetics (CYTK) stock has experienced downward pressure and recent insider selling, following a broader market reassessment of its Phase 3 trial data for aficamten presented at the European Society of Cardiology (ESC) Congress.
- −4.3%Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript: Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript [2026-09-14]
- +3.6%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −7.5%Cytokinetics fell 7.5% on August 28, 2026, despite announcing positive Phase 3 ACACIA-HCM trial results for aficamten in non-obstructive hypertrophic cardiomyopathy at the European Society of Cardiology Congress. Read the August 28, 2026 analysis →
Cytokinetics, Incorporated (CYTK) shares fell 1.3% to $50.78 as of November 22, 2026, a modest decline from the prior close of $51.46. BestStocks flagged the session as a material change for CYTK. Below, we break down what changed for CYTK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
CYTK fell 1.3% to $50.78
Cytokinetics declined 2.33% to $51.93 despite touting MYQORZO launch momentum and announcing plans for a new FDA filing, per MarketBeat. Volume was 306,024 shares (90 min in), tracking 0.67x the historical average for this time—below-average participation suggests retail and institutional investors are stepping back despite the positive product news. Cytokinetics earnings on 2027-02-23 (tentative); monitor for MYQORZO revenue ramp and timing of the announced FDA filing submission.
What it means for Cytokinetics, Incorporated investors
For Cytokinetics, Incorporated investors, the recent signals add up to a bearish shift. Weighing against that: Negative session, down 1.3%; Cytokinetics declined 2.33% to $51.93 despite touting MYQORZO launch momentum and announcing plans for a new FDA filing, per MarketBeat. Wall Street's consensus price target sits at $107.14, implying +111.0% upside from $50.78. BestStocks rates the overall signal quality weak (31/100). With earnings roughly 93 days out, the next report is the most likely near-term test of the move.
CYTK price reaction
CYTK last traded at $50.78, down $0.68 (-1.32%) from the previous close of $51.46. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $50.78 and $63.60, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Cytokinetics, Incorporated (CYTK)
The consensus analyst price target on Cytokinetics, Incorporated (CYTK) is $107.14, 111.0% above the recent $50.78. Over the past 90 days analysts logged 0 upgrades, 5 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CYTK line up.
The bullish case
- Wall Street's consensus price target of $107.14 implies +111.0% upside from $50.78.
- The Street's most bullish target is $118.00 (+132.4%).
The bearish case
- Negative session, down 1.3%.
- Cytokinetics declined 2.33% to $51.93 despite touting MYQORZO launch momentum and announcing plans for a new FDA filing, per MarketBeat.
- Cytokinetics announced expanded prescribing information for MYQORZO® (aficamten) incorporating Phase 3 MAPLE-HCM trial data, positioning the drug for a new heart-disease indication (Globe Newswire, 2026-11-16).
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CYTK
In-depth CYTK event analyses
Frequently asked questions about CYTK
Why did Cytokinetics, Incorporated (CYTK) stock move?
Cytokinetics, Incorporated (CYTK) fell 2.9% on November 17, 2026, closing at $51.65 versus $53.17 the prior session (close-to-close, from daily closes). Despite touting MYQORZO launch momentum and announcing plans for a new FDA filing, per MarketBeat. Volume was 306,024 shares (90 min in), tracking 0.67x the historical average for this time—below-average participation suggests retail and institutional investors are stepping back despite the positive product news. Source: marketbeat.com.
How much did CYTK stock fall?
CYTK lost 1.32% ($0.68) versus the prior close of $51.46, last trading at $50.78 on 0.7× average volume.
When is Cytokinetics, Incorporated's next earnings date?
CYTK's next earnings report is estimated for 2027-02-23 — about 93 days away.
What is the analyst price target for CYTK?
The consensus analyst price target for CYTK is $107.14, about 111.0% above the current $50.78. Over the past 90 days, analysts recorded 0 upgrades, 5 maintains, and 0 downgrades.
How BestStocks tracks CYTK
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared CYTK-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for CYTK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

